Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis

M. Battaglia Parodi, P. Iacono, C. La Spina, K. A. Knutsson, A. Mansour, J. F. Arevalo, F. Bandello

Research output: Contribution to journalArticle

Abstract

Purpose To assess the effects of intravitreal bevacizumab (IVB) in the treatment of choroidal neovascularisation (CNV) secondary to serpiginous choroiditis (SC). Design Non-randomised, interventional case series. Participants Seven patients (seven eyes) affected by juxtafoveal CNV (six eyes) and subfoveal CNV (one eye) associated with SC were recruited. Methods Each patient underwent an ophthalmological examination, including measurement of best-correced visual acuity (BCVA), fluorescein angiography (FA) and optical coherence tomography (OCT). After a first IVB injection (1.25 mg), patients were evaluated monthly over a 12-month follow-up. Further re-treatments were performed on the basis of detection of any type of fluid on OCT and/or presence of leakage on FA. The primary outcome considered was the median change in BCVA, as well as the proportion of eyes gaining at least 5 and 10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at the end of the 12-month follow-up. Secondary outcomes included median changes in central macular thickness (CMT) and number of injections over the planned follow-up. Results Median BCVA changed from 0.3 to 0.4 LogMAR. A functional improvement of at least 5 and 10 ETDRS letters was obtained in two eyes (28%) and one eye (14%), respectively, at the 12-month examination. Four eyes (57%) had stable BCVA, whereas one eye (14%) experienced a two-line decrease. Median CMT at baseline was 261 μm, decreasing to 196 μm at the 12-month examination. The median number of IVB injections was 1 in 12 months. Conclusions IVB can achieve anatomical stabilization of CNV secondary to SC, avoiding a decline in visual acuity, in almost 90% of cases over a 12-month followup.

Original languageEnglish
Pages (from-to)519-522
Number of pages4
JournalBritish Journal of Ophthalmology
Volume98
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Choroiditis
Choroidal Neovascularization
Visual Acuity
Intravitreal Injections
Fluorescein Angiography
Optical Coherence Tomography
Diabetic Retinopathy
Bevacizumab
Therapeutics
Injections

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Medicine(all)

Cite this

Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis. / Parodi, M. Battaglia; Iacono, P.; La Spina, C.; Knutsson, K. A.; Mansour, A.; Arevalo, J. F.; Bandello, F.

In: British Journal of Ophthalmology, Vol. 98, No. 4, 2014, p. 519-522.

Research output: Contribution to journalArticle

Parodi, M. Battaglia ; Iacono, P. ; La Spina, C. ; Knutsson, K. A. ; Mansour, A. ; Arevalo, J. F. ; Bandello, F. / Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis. In: British Journal of Ophthalmology. 2014 ; Vol. 98, No. 4. pp. 519-522.
@article{d92a7a5122c9416baa40ed0c62ef189a,
title = "Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis",
abstract = "Purpose To assess the effects of intravitreal bevacizumab (IVB) in the treatment of choroidal neovascularisation (CNV) secondary to serpiginous choroiditis (SC). Design Non-randomised, interventional case series. Participants Seven patients (seven eyes) affected by juxtafoveal CNV (six eyes) and subfoveal CNV (one eye) associated with SC were recruited. Methods Each patient underwent an ophthalmological examination, including measurement of best-correced visual acuity (BCVA), fluorescein angiography (FA) and optical coherence tomography (OCT). After a first IVB injection (1.25 mg), patients were evaluated monthly over a 12-month follow-up. Further re-treatments were performed on the basis of detection of any type of fluid on OCT and/or presence of leakage on FA. The primary outcome considered was the median change in BCVA, as well as the proportion of eyes gaining at least 5 and 10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at the end of the 12-month follow-up. Secondary outcomes included median changes in central macular thickness (CMT) and number of injections over the planned follow-up. Results Median BCVA changed from 0.3 to 0.4 LogMAR. A functional improvement of at least 5 and 10 ETDRS letters was obtained in two eyes (28{\%}) and one eye (14{\%}), respectively, at the 12-month examination. Four eyes (57{\%}) had stable BCVA, whereas one eye (14{\%}) experienced a two-line decrease. Median CMT at baseline was 261 μm, decreasing to 196 μm at the 12-month examination. The median number of IVB injections was 1 in 12 months. Conclusions IVB can achieve anatomical stabilization of CNV secondary to SC, avoiding a decline in visual acuity, in almost 90{\%} of cases over a 12-month followup.",
author = "Parodi, {M. Battaglia} and P. Iacono and {La Spina}, C. and Knutsson, {K. A.} and A. Mansour and Arevalo, {J. F.} and F. Bandello",
year = "2014",
doi = "10.1136/bjophthalmol-2013-304237",
language = "English",
volume = "98",
pages = "519--522",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Intravitreal bevacizumab for choroidal neovascularisation in serpiginous choroiditis

AU - Parodi, M. Battaglia

AU - Iacono, P.

AU - La Spina, C.

AU - Knutsson, K. A.

AU - Mansour, A.

AU - Arevalo, J. F.

AU - Bandello, F.

PY - 2014

Y1 - 2014

N2 - Purpose To assess the effects of intravitreal bevacizumab (IVB) in the treatment of choroidal neovascularisation (CNV) secondary to serpiginous choroiditis (SC). Design Non-randomised, interventional case series. Participants Seven patients (seven eyes) affected by juxtafoveal CNV (six eyes) and subfoveal CNV (one eye) associated with SC were recruited. Methods Each patient underwent an ophthalmological examination, including measurement of best-correced visual acuity (BCVA), fluorescein angiography (FA) and optical coherence tomography (OCT). After a first IVB injection (1.25 mg), patients were evaluated monthly over a 12-month follow-up. Further re-treatments were performed on the basis of detection of any type of fluid on OCT and/or presence of leakage on FA. The primary outcome considered was the median change in BCVA, as well as the proportion of eyes gaining at least 5 and 10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at the end of the 12-month follow-up. Secondary outcomes included median changes in central macular thickness (CMT) and number of injections over the planned follow-up. Results Median BCVA changed from 0.3 to 0.4 LogMAR. A functional improvement of at least 5 and 10 ETDRS letters was obtained in two eyes (28%) and one eye (14%), respectively, at the 12-month examination. Four eyes (57%) had stable BCVA, whereas one eye (14%) experienced a two-line decrease. Median CMT at baseline was 261 μm, decreasing to 196 μm at the 12-month examination. The median number of IVB injections was 1 in 12 months. Conclusions IVB can achieve anatomical stabilization of CNV secondary to SC, avoiding a decline in visual acuity, in almost 90% of cases over a 12-month followup.

AB - Purpose To assess the effects of intravitreal bevacizumab (IVB) in the treatment of choroidal neovascularisation (CNV) secondary to serpiginous choroiditis (SC). Design Non-randomised, interventional case series. Participants Seven patients (seven eyes) affected by juxtafoveal CNV (six eyes) and subfoveal CNV (one eye) associated with SC were recruited. Methods Each patient underwent an ophthalmological examination, including measurement of best-correced visual acuity (BCVA), fluorescein angiography (FA) and optical coherence tomography (OCT). After a first IVB injection (1.25 mg), patients were evaluated monthly over a 12-month follow-up. Further re-treatments were performed on the basis of detection of any type of fluid on OCT and/or presence of leakage on FA. The primary outcome considered was the median change in BCVA, as well as the proportion of eyes gaining at least 5 and 10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at the end of the 12-month follow-up. Secondary outcomes included median changes in central macular thickness (CMT) and number of injections over the planned follow-up. Results Median BCVA changed from 0.3 to 0.4 LogMAR. A functional improvement of at least 5 and 10 ETDRS letters was obtained in two eyes (28%) and one eye (14%), respectively, at the 12-month examination. Four eyes (57%) had stable BCVA, whereas one eye (14%) experienced a two-line decrease. Median CMT at baseline was 261 μm, decreasing to 196 μm at the 12-month examination. The median number of IVB injections was 1 in 12 months. Conclusions IVB can achieve anatomical stabilization of CNV secondary to SC, avoiding a decline in visual acuity, in almost 90% of cases over a 12-month followup.

UR - http://www.scopus.com/inward/record.url?scp=84896545632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896545632&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2013-304237

DO - 10.1136/bjophthalmol-2013-304237

M3 - Article

C2 - 24414400

AN - SCOPUS:84896545632

VL - 98

SP - 519

EP - 522

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 4

ER -